Cybersecurity is no longer a one-time regulatory hurdle—it is a continuous, lifecycle responsibility. As medical devices become increasingly connected, FDA expectations now extend beyond premarket documentation to include ongoing monitoring, vulnerability management, and real-world risk response.
RQMIS, in partnership with Twin Tech Labs, delivers an integrated cybersecurity solution that combines regulatory expertise with a modern, AI-driven security operations platform. This approach enables medical device and SaMD companies to meet both premarket and post-market cybersecurity expectations—without building internal security teams or relying heavily on contractors.
Our expanded cybersecurity offering is powered by Arca, a self-hosted security operations platform, and Nemesis, an advanced breach and attack simulation engine. Together, they allow us to deliver:
This model replaces fragmented, manual cybersecurity efforts with a consistent, scalable solution aligned to regulatory expectations.
We support development of cybersecurity documentation aligned with FDA guidance, including:
Using Nemesis, we simulate real-world attack scenarios across network, infrastructure, web applications, and APIs.
Mobile application testing is supported through targeted engagements when needed.
Arca produces auditor-ready reports based on real system activity—not static documentation.
Supported frameworks include:
This eliminates manual evidence collection and ensures audit readiness at any time.
To meet post-market surveillance expectations, Arca enables ongoing visibility into system activity:
This provides a turnkey solution for demonstrating ongoing cybersecurity monitoring and risk management.
Technology alone isn’t enough. RQMIS bridges the gap between cybersecurity data and regulatory expectations by:
This approach allows clients to:
Whether you are preparing for FDA submission or strengthening your post-market surveillance program, RQMIS can help you implement a modern, scalable cybersecurity strategy.